Therapy of metabolic disorders with intravenous (IV) access ports and long term intravenous L-carnitine therapy.
With the expansion of newborn screening to include many organic acidurias and fatty acid oxidation defects, effective therapies of these disorders will be needed. Currently severe disorders such as methylmalonic and propionic aciduria. conventional therapy with diet and oral L-camitine often prove ineffective in preventing failure to thrive and recurrent metabolic decompensations. L-carnitine provides a natural pathway for removal of the toxic metabolites in these disorders and is life saving therapy but, with poor oral absorption (25%), it is difficult to supply adequate carnitine to meet the metabolic needs of these patients. Long term intravenous L-carnitine therapy, administered through a subcutaneous venous access port in 5 patients with organic acidurias [propionic aciduria (2), methylmalonic aciduria (2), 3 methylglutaconic aciduria(1)] resulted in improved growth, lower frequency of metabolic decompensations and increased tolerance of natural protein in the diet. An added benefit was the ability to initiate fluid. electrolytes, and antibiotics during metabolic decompensations at home thus averting hospitalizations.
Winter
S
S
Valley Children's Hospital, Madera, CA, USA.
Birek
L
L
Walker
T
T
Phalin-Roque
J
J
Chandler
M J
MJ
Field
C
C
Zorn
E
E
D002331:Carnitine / Q000008:administration & dosage*; D002408:Catheters, Indwelling; D005260:Female; D006801:Humans; D007262:Infusions, Intravenous; D008661:Metabolism, Inborn Errors / Q000628:therapy*; D008764:Methylmalonic Acid / Q000652:urine; D011422:Propionates / Q000652:urine
D011422:Propionates; D008764:Methylmalonic Acid; D002331:Carnitine